Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Travere Therapeutics (NASDAQ:TVTX) had its target price increased by investment analysts at Wells Fargo & Company from $40.00 to $50.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 14.58% from the company’s previous close.

A number of other equities research analysts also recently commented on TVTX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Guggenheim boosted their price objective on Travere Therapeutics from $54.00 to $56.00 and gave the company a “buy” rating in a report on Friday, April 24th. TD Cowen boosted their price objective on Travere Therapeutics from $45.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. decreased their price objective on Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a report on Wednesday, March 25th. Finally, Canaccord Genuity Group boosted their price objective on Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.83.

Travere Therapeutics Stock Performance

Shares of Travere Therapeutics stock traded down $1.16 on Wednesday, reaching $43.64. 431,924 shares of the stock were exchanged, compared to its average volume of 2,143,451. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71. Travere Therapeutics has a twelve month low of $13.88 and a twelve month high of $48.61. The firm has a market capitalization of $4.03 billion, a price-to-earnings ratio of -189.91 and a beta of 1.13. The business has a 50 day moving average price of $32.31 and a two-hundred day moving average price of $32.71.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 28.38% and a negative net margin of 4.00%.The firm had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. During the same quarter in the previous year, the company posted ($0.47) earnings per share. The company’s revenue was up 55.6% compared to the same quarter last year. Analysts anticipate that Travere Therapeutics will post -0.16 earnings per share for the current fiscal year.

Insider Activity at Travere Therapeutics

In related news, CFO Christopher R. Cline sold 1,014 shares of the firm’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $42.61, for a total transaction of $43,206.54. Following the sale, the chief financial officer owned 116,899 shares in the company, valued at approximately $4,981,066.39. This trade represents a 0.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider William E. Rote sold 9,100 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $39.09, for a total transaction of $355,719.00. Following the sale, the insider owned 113,987 shares in the company, valued at approximately $4,455,751.83. This represents a 7.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 310,852 shares of company stock valued at $11,890,666 in the last quarter. 4.44% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Travere Therapeutics by 10.3% during the third quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company’s stock valued at $158,059,000 after acquiring an additional 619,085 shares during the last quarter. State Street Corp raised its holdings in shares of Travere Therapeutics by 47.8% during the fourth quarter. State Street Corp now owns 4,756,666 shares of the company’s stock valued at $181,752,000 after acquiring an additional 1,538,827 shares during the last quarter. Perceptive Advisors LLC raised its holdings in shares of Travere Therapeutics by 12.7% during the fourth quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company’s stock valued at $163,469,000 after acquiring an additional 483,565 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Travere Therapeutics by 27.4% during the second quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company’s stock valued at $41,203,000 after acquiring an additional 599,102 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Travere Therapeutics by 28.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company’s stock valued at $85,849,000 after acquiring an additional 494,665 shares during the last quarter.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target to $60 and maintained a Buy rating, signaling >30% upside vs. recent levels and offering bullish analyst support for the stock. TD Cowen raises target to $60 (Benzinga)
• Positive Sentiment: Corporate update: management highlighted the FDA approval of FILSPARI in FSGS, strong demand for FILSPARI in IgAN, and the resumption of patient dosing in the pegtibatinase Phase 3 HARMONY study — operational catalysts that support longer‑term revenue upside. Travere Therapeutics Reports First Quarter 2026 Financial Results (BusinessWire)
• Neutral Sentiment: Q1 results were mixed: EPS beat (reported $0.05 vs. consensus -$0.24) but revenue missed ($127.2M vs. ~$136.2M est). Revenue growth was strong year-over-year (~+55.6%), but the top-line miss gives investors a reason to be cautious near-term. Q1 2026 press release / slide deck
• Neutral Sentiment: HC Wainwright kept a Buy rating and a $57 target but trimmed long‑range EPS forecasts modestly for FY2027–FY2030 (small downgrades to FY2027–2030 numbers). The firm’s continued Buy stance tempers the impact of the small cuts.
• Negative Sentiment: Insider selling: Director Roy Baynes sold 9,750 shares under a pre-arranged Rule 10b5‑1 plan (avg. ~$44.22). While disclosed as plan-based (reducing governance concern), the trade can still put short-term pressure on sentiment. SEC Form 4 (Roy Baynes sale)

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.